Biological insights into BRAFv600 mutations in melanoma patient not mere therapeutic targets

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Improta, Giuseppina ^a   Pelosi, Giuseppe ^b,c   Tamborini, Elena ^b   Donia, Marco ^d,e   Santinami, Mario ^b   De Braud, Filippo ^b   Fraggetta, Filippo ^f  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF CATANIA   (Italy)

^f CANNIZZARO HOSPITAL   (Italy)

Author keywords

BRAF; Homozygosis; Immunotherapy; Melanoma; MHC; Vemurafenib

Indexed keywords

ALBINTERFERON ALPHA2B; B RAF KINASE; GAMMA INTERFERON; GENOMIC DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; BRAF GENE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; MELANOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84885736449     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25594     Document Type: Article

References (10)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766
2. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/ NEJMoa1112302
3. Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-? enhances anticancer responses of cell products for infusion. J Invest Dermatol 2013; 133:545- 52; PMID:23014345; http://dx.doi.org/10.1038/ jid.2012.336
4. Cangemi G, Morandi B, D'Agostino A, Peri C, Conte R, Damonte G, et al. IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. Int Immunol 2003; 15:1415-21; PMID:14645150; http://dx.doi.org/10.1093/intimm/dxg140
5. Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2013; 2:e22890; PMID:23483066; http://dx.doi. org/10.4161/onci.22890
6. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8:67; PMID:20630094; http://dx.doi. org/10.1186/1479-5876-8-67
7. Sigalotti L, Fratta E, Parisi G, Coral S, Maio M. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success. Br J Cancer 2011; 105:327-8; PMID:21694724; http:// dx.doi.org/10.1038/bjc.2011.239
8. Jönsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringnér M, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007; 26:4738-48; PMID:17260012; http://dx.doi.org/10.1038/sj.onc.1210252
9. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, et al. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 2004; 23:8796-804; PMID:15467732; http://dx.doi.org/10.1038/ sj.onc.1208152
10. Tischfield JA. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am J Hum Genet 1997; 61:995-9; PMID:9345110; http://dx.doi.org/10.1086/301617